Tezacaftor/Ivacaftor Receives FDA Approval for Patients Ages 6 and Older with Cystic Fibrosis - Pharmacy Times

Tezacaftor/Ivacaftor Receives FDA Approval for Patients Ages 6 and Older with Cystic Fibrosis  Pharmacy Times

Officials with the FDA today expanded the indication for tezacaftor/ivacaftor (Symdeko, Vertex) tablets for the treatment of pediatric patients ages 6 years and ...


-

Comments

Post a Comment

Popular Posts

Community-Acquired Pneumonia: Symptoms and Treatment - Verywell Health

Image
There are several ways that you can develop pneumonia ranging from inhaling toxic substances in the workplace to unknowingly being infected by a bacteria in the hospital. Any lung infection acquired outside of the hospital setting is considered community-acquired pneumonia (CAP). Viruses and certain bacteria such as streptococcus pneumoniae (S. pneumoniae), haemophilus influenzae, and atypical bacteria—like chlamydia pneumoniae, mycoplasma pneumoniae, and Legionella species—are among the most common culprits of CAP. This article discusses the symptoms, causes, treatment, and prognosis for community-acquired pneumonia. Mongkol Chuewong / Getty Images Symptoms The clinical presentation of CAP varies wildly depending on the range. For example: Mild pneumonia is characterized by fever and a productive cough. Severe pneumonia is characterized by difficulty breathing and sepsis. Symptoms of CAP often develop quickly and are ac...
Read more

Dengue – the Region of the Americas - World Health Organization

Image
Situation at a glance Since the beginning of 2023, dengue outbreaks of significant magnitude have been recorded in the WHO Region of the Americas, with close to three million suspected and confirmed cases of dengue reported so far this year, surpassing the 2.8 million cases of dengue registered for the entire year of 2022. Of the total number of dengue cases reported until 1 July 2023 (2 997 097 cases), 45% were laboratory confirmed, and 0.13% were classified as severe dengue. The highest number of dengue cases to date in 2023 are in Brazil, Peru, and Bolivia. Additionally, 1302 deaths were reported in the Region with a Case Fatality Rate (CFR) of 0.04%, in the same period. As part of the implementation of the Integrated Management Strategy for the Prevention and Control of Arboviral Diseases (IMS-Arbovirus), WHO is actively working with the Member States to strengthen healthcare and surveillance capacity. WHO has assessed the risk of dengue as high at the regional level due to the w...
Read more